Vermillion Wins Medi-Cal Coverage for OVA1 | GenomeWeb

NEW YORK (GenomeWeb) – Vermillion said today that Medi-Cal, California's Medicaid program, now supports the company's OVA1 ovarian cancer test in its medical policy guidelines.

According to Vermillion, Medi-Cal covers more than 12.6 million lives, or roughly a third of the covered lives in California.

OVA1 measures levels of five proteins in patient blood and is intended for triaging patients with ovarian adnexal masses as part of preoperative evaluations to determine the likelihood that a mass is cancerous.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.